Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Jim Dentzer – President and Chief Executive Officer Soumit Roy – Jones Trading Operator I would now like to turn the conference over to Diantha Duvall, CurisÂ' Chief Financial Officer. Ms. Diantha, please go ahead. Thank you, and welcome to CurisÂ' second quarter 2023 business update call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com ...

Condensed Consolidated Statements of Stockholders' Equity (In thousands, except share data) (Unaudited) | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------|--------------------------------|-----------|------------------|-------|------------------------------------------|-------|-------|-----------------------------------|------------|----------------------------------------------------|-------|------------------ ...

General and administrative expenses were $4.8 million for the first quarter of 2023 as compared to $5.7 million for the same period in 2022. The decrease in general administrative expenses was driven primarily by lower employee related costs due to reduction in headcount. For the first quarter of 2023, other income net was $0.1 million as compared to other expense net of 1 million for the same period in 2022. Other income expense net primarily consists of interest income partially offset by expense related ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3505116 (State or Other Jurisdiction of ...

财务数据和关键指标变化 - 2022年第四季度净亏损1130万美元,较2021年同期1360万美元有所下降 [12] - 2022年全年净亏损5670万美元,较2021年同期4540万美元有所增加 [12] - 2022年第四季度收入2900万美元,较2021年同期3100万美元略有下降 [12] - 2022年全年收入1020万美元,较2021年同期1060万美元略有下降 [12] - 2022年第四季度研发费用870万美元,较2021年同期1080万美元有所下降 [13] - 2022年全年研发费用4330万美元,较2021年同期3490万美元有所增加 [13] - 2022年第四季度管理费用430万美元,较2021年同期480万美元有所下降 [13] - 2022年全年管理费用1960万美元,较2021年同期1730万美元有所增加 [13] 各条业务线数据和关键指标变化 - 公司目前正在进行两项临床试验:TakeAim Leukemia研究和TakeAim Lymphoma研究 [7][10] - TakeAim Leukemia研究中,FLT3突变AML患者完全缓解率为29%,有剑突变AML患者完全缓解/部分缓解率为22%,有剑突变MDS患者总反应率为45% [7] - TakeAim Lymphoma研究正在关注原发中枢神经系统淋巴瘤,采用emavusertib和伊布替尼的联合治疗 [10] 各个市场数据和关键指标变化 - 未提及具体市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司正在与FDA合作解决TakeAim Leukemia研究的临时临床暂停问题,预计将于2023年第三季度与FDA会面 [8][9] - 公司暂时将资金集中于IRAK4项目,暂时搁置VISTA项目,待财务状况好转后再考虑重启 [21][22] - 公司认为emavusertib是一种重要的治疗选择,可满足目前AML和MDS患者的关键未满足需求 [7] 管理层对经营环境和未来前景的评论 - 公司对emavusertib在AML和MDS治疗中的潜力感到兴奋,认为这是一种重要的治疗替代方案 [7] - 公司对TakeAim Leukemia和TakeAim Lymphoma研究的进展感到满意,并期待在2023年底前提供更新 [19][39] - 公司认为目前的财务状况良好,现有现金和投资应能维持至2025年 [15] 问答环节重要的提问和回答 问题1 **Ed White 提问** 询问TakeAim Lymphoma研究何时会有数据更新 [18] **James Dentzer 回答** 公司预计在2023年底前提供TakeAim Lymphoma研究的数据更新 [19] 问题2 **Soumit Roy 提问** 询问新增9名患者的具体情况 [26][27] **Robert Martell 回答** 新增9名患者包括AML和MDS患者,大多数为晚期患者,与之前入组的患者情况相似 [27][28] 问题3 **Yale Jen 提问** 询问新增9名患者与之前患者是否存在差异 [31] **Robert Martell 回答** 新增9名患者与之前患者基本相似,都是晚期难治患者,未来公司会选择更有针对性的患者群进行研究 [32]

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | (in thousands) \nAssets: | 2022 | | | 2021 | | Operating lease right-of-use asset | $ | 4,401 | $ | 5,749 | | | | | | | | Liabilities: | | | | | | Operating lease liability - short-term | $ | 1,141 | $ | 682 | | Operating lease liability - long-term | $ | 2,800 | $ | 4,358 | | Total operating liability | $ | 3,941 | $ | 5,040 | | --- | --- | --- | --- | --- | |-------------------------------- ...

Curis, Inc. (NASDAQ:CRIS) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Craig West – Vice President-Investor Relations and Corporate Communications Jim Dentzer – President and Chief Executive Officer Diantha Duvall – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Soumit Roy – Jones Research Li Watsek – Cantor Fitzgerald Operator Good afternoon, and welcome to Curis' Third Quarter 2022 Business Update Call. All participants will be in liste ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact N ...

Corporate Presentation NASDAQ: CRIS Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect(s)," "believe(s)," "will," "may," "anticipate(s)," "focus(es)," "plans," "mission," "strategy," "potential," "estimate(s)", "intend," "project," "seek," "should," "would" and similar expressions are int ...

Curis, Inc. (NASDAQ:CRIS) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Craig West - VP, IR & Corporate Communications Jim Dentzer - President & CEO Bill Steinkrauss - CFO & Chief Administrative Officer Conference Call Participants Soumit Roy - JonesResearch Li Watsek - Cantor Fitzgerald Bob Martell - Head, Research and Development Operator Good afternoon, everyone, and welcome to Curis' second quarter 2022 earnings conference call. [Operator instructions] At this time, I'd ...